Natera: High Demand for Precise Diagnostics and Innovations like the “Empower” Panel Spark Buying Interest - Stock Price Surges by Around 20%!

Q2 revenue grows by 37.7% to $752.8 million with a gross margin of 64.5%. Nearly 297,000 processed cancer tests demonstrate high clinical demand. Management raises annual revenue forecast to up to $2.91 billion. Cell-Free DNA Analyses as a Clinical Foundation Natera (NTRA) focuses on non-invasive analysis of cell-free DNA, addressing complex medical questions. A key growth driver is the Signatera test for detecting minimal residual disease. The method is tumor-specific and analyzes circulating tumor DNA in the blood. Based on new study...